Shares of Ocugen (NASDAQ: OCGN) were skyrocketing 64.2% higher as of 11:35 a.m. EST on Monday. As of this writing, Matt did not hold a position in any of theaforementioned securities. OCGN | Ocugen Inc. Stock Price & News - WSJ The stock dropped as low as 26 cents during the height of the pandemic fears in March 2020. Histogenics itself highlights the risks involved in small-cap biotech. According to the prospectus, the combined company posted an operating loss of roughly $30 million in 2018. When the symbol you want to add appears, add it to Watchlist by selecting it and pressing Enter/Return. Investors should definitely reevaluate Ocugen's prospects in light of the company's bad news announced last week. 1125 N. Charles St, Baltimore, MD 21201. Copyright The S&P 500 has rallied 52.9% from the March low to its highs on August 6. In other words, it means that even by biotech standards OCGN stock is an enormously risky play. Written by Ocugen shares jumped to $3.50 on massive volume in December when the Covaxin partnership was announced. The Ocugen deal is a way to salvage some limited value. You'll now be able to see real-time price and activity for your symbols on the My Quotes of Nasdaq.com. You canfollow Will on Twitterat @HealyWriting. Like other life sciences companies involved in Covid-19 vaccine. That doesnt mean success is guaranteed. Do Not Sell My Personal Information (CA Residents Only). The chances of anything more are small but the rewards could be huge. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services. 10 stocks we like better than Ocugen, Inc.When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. But the allure of the space is that when a company wins, its shareholders win big. There's a pretty good case to be made that other stocks offer even better prospects for returns with lower risk than Ocugen does. Importantly, neither Bharat nor Indian regulators revealed the efficacy of the vaccine. Histogenics shareholders then received about 14% of the company, according to the merger prospectus. However, the Strong Buy consensus rating is backed with a $0.9 price target, which implies downside of 68% from current levels. Copyright CanSinoBio will receive some of the profits, but Ocugen still would skyrocket with FDA approval and ensuing revenue and there are more products in the pipeline. On June 10, though, Ocugen announced that the U.S. Food and Drug Administration (FDA) had effectively shut the door on an EUA filing. Its top officers have experience at Pfizer (NYSE:PFE) and other well-respected pharmaceutical and biotechnology companies. Nano-cap biotech play Ocugen has an intriguing story and a ton of risk. Ocugen Stock Crashes: What Should Investors Do Now? Assuming it wins approval for the vaccine, the challenge for the company then will be to achieve commercial success. Malvern-based biopharmaceutical company Ocugen completed its previously announced $100 million private stock sale. Companies will inevitably be optimistic about their prospects for success (at least publicly). With no effective treatments, and without a clear reason to exist, I would avoid buying Ocugen stock even as a speculative play. OCGN - Ocugen Inc Forecast - CNNMoney.com - CNN Business Stock Price Forecast The 6 analysts offering 12-month price forecasts for Ocugen Inc have a median target of 4.75, with a high estimate of 8.00 and a low estimate of 3.00. Outsmart the market with Smart Portfolio analytical tools powered by TipRanks. Don't overlook another approach, especially if you're still sitting on a nice gain even after last week's major sell-off. Type a symbol or company name. Considering Bharats reputation for world-class R&D and manufacturing capabilities in vaccines and bio-therapeutics, H.C. Wainwright analyst Swayampakula Ramakanth thinks the company is a suitable partner.. Just a few days ago, Ocugen (NASDAQ: OCGN) was flying high with shares up more than 460% year to date. Ocugen announced in late Decemberit had signed a letter of intent to co-develop COVID-19 vaccine candidate Covaxin along with Indian pharmaceutical company Bharat Biotech. Article printed from InvestorPlace Media, https://investorplace.com/2019/12/no-pathway-forward-for-ocugen-stock/. Start trading Options with Saxo today. Is Ocugen Stock Still Worth Buying After Its 800%-Plus Rally? Analyst 7 Travel Stocks to Buy Banking On Pent-Up Demand. Sign up below to get this incredible offer! Ocugen - Stock Price History | OCGN | MacroTrends Add in a $31 million market capitalization and potentially significant cash burn, and Ocugen stock self-evidently is not for risk-averse investors. The biotech stock promptly crashed by more than 30%. That's right -- they think these 10 stocks are even better buys. Unfortunately, when the market bounced in late March 2020, Ocugen kept heading lower. In the late summer of 2018, the stock crashed below $1 per share as investors sold off following a failed phase three trial. While it feels cool to buy a thousand shares of OCGN stock vs. a few shares of Amazon (NASDAQ:AMZN), save yourself the heartache. When the market crashed during the U.S. pandemic outbreak in March, shares of vaccine makers understandably soared as work began on developing vaccines to fight COVID-19. The equity has experienced a continual decline for years. Conditions only seem to get worse for Ocugen (NASDAQ:OCGN). It peaked at a split-adjusted level of around $778 per share soon after its initial public offering in 2014. Type a symbol or company name. The risk-reward proposition for Ocugen is obviously much different now than it was when individuals were buying the stock over the last several months. quotes delayed at least 15 minutes, all others at least 20 minutes. OCGN Stock Forecast 2022 and 2025: Is Ocugen Set to Explode? Maybe. However, due to the fact the details of the definitive agreement have yet to be finalized, in addition to the current lack of insight into the U.S. regulatory pathway or commercial strategy, Ramakanth stays on the sidelines for now. We have provided a few examples below that you can copy and paste to your site: Your image export is now complete. But if they do, Ocugen stock at the least looks like an intriguing bet. It is focused on discovering, developing and commercializing therapies which address rare and underserved eye diseases. Typically, I care little about financials with biotechs. That pathway will likely require the company to conduct further clinical testing of the vaccine in the U.S. Are there any other near-term catalysts for the biotech stock? Even before that point, the most promising candidates generally can find funding. The FDA's decision not to issue EUA really wasn't all that surprising, though. Disclaimer: The opinions expressed in this article are solely those of the featured analysts. Still, Ocugen investors who bought one year ago and held on have generated a huge return on their investment. Ocugen has responded to Health Canada regarding deficiencies identified with its regulatory filing for Covaxin. Covaxin doesn't have an advantage in terms of dosing compared to these leading vaccines. Ocugen Inc First Quarter 2022 Financial Results and Recent Business Highlights 04/21/2022 Noble Capital Markets' Eighteenth Annual Investor Conference 03/14/2022 34th Annual ROTH Conference 02/25/2022 Ocugen, Inc. Q4 and Full Year 2021 Financial Results and Recent Business Highlights 01/10/2022 H.C. Wainwright Bioconnect Conference 12/22/2021 Shares of Ocugen (OCGN) skyrocketed over 800% in the past three trading sessions after the biopharmaceutical company disclosed it had signed a binding letter of intent (LOI) with India based Bharat Biotech to co-develop a COVID-19 vaccine for the U.S. market. OCGN does not even appear to have an apparent reason to exist. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*. Will Be Even Bigger Than Your Wildest Expectation, 7 Over-$100 Stocks That Are Worth Every Penny, Louis Navellier and the InvestorPlace Research Staff, 5 Penny Cryptos With the Most Potential for Growth. Keith Speights has no position in any of the stocks mentioned. An unprofitable biotech that focused on commercializing therapies to cure blindness prior to the present pandemic, Ocugen ( OCGN) stock took on a new life on December 22, when it announced. (See OCGN stock analysis on TipRanks). For now, though, what happens in India stays in India. Ocugen does have at least 180 days to cure that problem, but the simplest answer is for the company to execute a reverse stock split. Theres even room for more lines. Indeed, the price broke below the 24 December 2018 low at 4.81 and is currently attempting a return move. Accordingly, the analyst rates OCGN a Neutral (i.e. The content is intended to be used for informational purposes only. *Stock Advisor returns as of November 20, 2020. The statistics support having long-term exposure to this asset class. I am all for a good opportunity, but I dont know why some investors insist on penny stocks. Historical daily share price chart and data for Ocugen since 2023 adjusted for splits. OCU300 already has received an orphan drug designation from the U.S. Food & Drug Administration for oGVHD; there is no currently approved treatment in the U.S. In fact, $1,000 in Ocugen stock bought on Aug. 9, 2020, would be worth about $15,100 today. You could sell some or all of your Ocugen shares and buy long-term call options on the stock. The worst news was that another late-stage clinical study will likely be required to support the regulatory filing. Even though Ocugen did raise $25 million in a private placement, the story behind OCU300 clearly was not enough to support an initial public offering on its own. Ill be sticking to the stocks that are actually working. However, I wont be around to find out. But the sale of NeoCart appears to not yet have closed after its deadline was extended to allow Medavate to secure financing. The huge gain came after the company's partner, Bharat Biotech, received emergency use authorization (EUA) in India for COVID-19 vaccine Covaxin. 2023 InvestorPlace Media, LLC. The odds of Ocugen stock winding up at zero are material. Please check your download folder. Ocugen ( NASDAQ: OCGN) has been one of the more polarizing story stocks of 2021. Still, Ocugen investors who bought one year ago and held on have generated a huge return on their. The Motley Fool recommends Moderna Inc. 1 Reason to Buy Ocugen in 2023 and 2 Reasons to Sell, 3 Under-the-Radar Stocks With 590% to 772% Upside in 2023, According to Wall Street, 2 Reasons to Avoid a Roth 401(k) for Your Retirement Savings, Warren Buffett's Latest $2.9 Billion Buy Brings His Total Investment in This Stock to $66 Billion in 4 Years, Want $1 Million in Retirement? InvestorPlace - Stock Market News, Stock Advice & Trading Tips. The Motley Fool has a disclosure policy. The FDA told the company in June 2021 that it should instead follow the standard path to full approval of the vaccine in adults. OCGN Ocugen Inc 155,223 $0.9721 $0.0263 (2.63%) Bharat's offering COVAXIN, a whole-viron inactivated COVID-19 vaccine candidate, has already shown promise in Phase 1 and 2 clinical trials in India and the enrollment of 26,000 subjects for the Phase 3 study is currently underway. It's easy to become such a huge fan of a stock that you lose objectivity about its prospects. Looking ahead, analysts are skeptical Covaxin will provide the upside Ocugen bulls are expecting.